Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.37)
# 371
Out of 5,006 analysts
107
Total ratings
55.43%
Success rate
17.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $52 → $66 | $67.95 | -2.87% | 5 | Aug 19, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 → $10 | $6.23 | +60.64% | 3 | Aug 18, 2025 | |
| PASG Passage Bio | Maintains: Buy | $260 → $67 | $8.00 | +737.50% | 7 | Aug 14, 2025 | |
| GUTS Fractyl Health | Maintains: Buy | $12 → $6 | $1.47 | +309.56% | 1 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $11 → $14 | $4.42 | +216.74% | 11 | Aug 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $136 → $128 | $30.19 | +323.98% | 9 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $424 → $411 | $402.90 | +2.01% | 9 | Aug 6, 2025 | |
| WVE Wave Life Sciences | Initiates: Buy | $19 | $7.21 | +163.52% | 1 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $390 → $415 | $452.00 | -8.19% | 9 | Aug 1, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 → $10 | $3.19 | +213.97% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $105 | $97.86 | +7.30% | 8 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $54 | $20.54 | +162.90% | 6 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $66 | $21.01 | +214.14% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $1.72 | +248.84% | 6 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $23.26 | +544.88% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $55.61 | +51.05% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $113.58 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $6.16 | +3,796.10% | 4 | Jul 23, 2019 |
Palvella Therapeutics
Aug 19, 2025
Maintains: Buy
Price Target: $52 → $66
Current: $67.95
Upside: -2.87%
Generation Bio Co.
Aug 18, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $6.23
Upside: +60.64%
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $260 → $67
Current: $8.00
Upside: +737.50%
Fractyl Health
Aug 14, 2025
Maintains: Buy
Price Target: $12 → $6
Current: $1.47
Upside: +309.56%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.42
Upside: +216.74%
Ultragenyx Pharmaceutical
Aug 8, 2025
Maintains: Buy
Price Target: $136 → $128
Current: $30.19
Upside: +323.98%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Hold
Price Target: $424 → $411
Current: $402.90
Upside: +2.01%
Wave Life Sciences
Aug 4, 2025
Initiates: Buy
Price Target: $19
Current: $7.21
Upside: +163.52%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $390 → $415
Current: $452.00
Upside: -8.19%
Rocket Pharmaceuticals
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.19
Upside: +213.97%
Jul 18, 2025
Maintains: Buy
Price Target: $92 → $105
Current: $97.86
Upside: +7.30%
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $20.54
Upside: +162.90%
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $21.01
Upside: +214.14%
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $1.72
Upside: +248.84%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $23.26
Upside: +544.88%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $55.61
Upside: +51.05%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $113.58
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $6.16
Upside: +3,796.10%